The Patent Finder

Method of Treating Expressive Language Deficit in Autistic Humans

AMS AG

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 11,980,603Method of Treating Expressive Language Deficit in Autistic Humans
In force
 · High confidence
UsedRemaining
AMS TherapeuticsIn forceHigh confidence
US 12,599,581Method of Treating Expressive Language Deficit in Autistic Humans
In force
 · Medium confidence
AMS Therapeutics, LLCIn forceMedium confidence
Application 18/620,897Method of Treating Expressive Language Deficit in Autistic Humans
Abandoned
Abandoned Mar 12, 2026
AMS TherapeuticsAbandonedAbandoned Mar 12, 2026
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by AMS AG.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited